Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Ba, Qian ^a   Zhou, Naiyuan ^b   Duan, Juan ^a   Chen, Tao ^a   Hao, Miao ^a   Yang, Xinying ^a   Li, Junyang ^a   Yin, Jun ^a   Chu, Ruiai ^a   Wang, Hui ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b China National Center for Biotechnology Development   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CD71 ANTIGEN; DIHYDROARTEMISININ; IRON; NYSTATIN; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL MEMBRANE; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENDOCYTOSIS; GENETIC TRANSFECTION; HOMEOSTASIS; HUMAN; HUMAN CELL; INTERNALIZATION; IRON DEPLETION; LIPID RAFT; OXIDATIVE STRESS; PALMITOYLATION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL LINE, TUMOR; CELL MEMBRANE; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; INTRACELLULAR SPACE; IRON; MEMBRANE MICRODOMAINS; NEOPLASMS; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 84865009936     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042703     Document Type: Article

References (33)

1. Hsu E, (2006) The history of qing hao in the Chinese materia medica. Trans R Soc Trop Med Hyg 100: 505-508.
2. Miller LH, Su XZ, (2011) Artemisinin: Discovery from the Chinese Herbal Garden. Cell 146: 855-858.
3. Tu Y, (2011) The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 17: 1217-1220.
4. Hou J, Wang D, Zhang R, Wang H, (2008) Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 14: 5519-5530.
5. Chen T, Li M, Zhang R, Wang H, (2009) Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 13: 1358-1370.
6. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, et al. (2010) Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anti-Cancer Drugs 21: 423-432.
7. O'Neill PM, Barton VE, Ward SA, (2010) The molecular mechanism of action of artemisinin-the debate continues. Molecules 15: 1705-1721.
8. Firestone GL, Sundar SN, (2009) Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 11: e32.
9. Chaturvedi D, Goswami A, Saikia PP, Barua NC, Rao PG, (2010) Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chem Soc Rev 39: 435-454.
10. Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, et al. (2008) Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther 7: 1017-1023.
11. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, et al. (2007) Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One 2: e798.
12. Rouault TA, (2006) The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2: 406-414.
13. Neckers LM, Trepel JB, (1986) Transferrin receptor expression and the control of cell growth. Cancer Invest 4: 461-470.
14. Graham RM, Chua AC, Herbison CE, Olynyk JK, Trinder D, (2007) Liver iron transport. World J Gastroenterol 13: 4725-4736.
15. Ponka P, Lok CN, (1999) The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 31: 1111-1137.
16. Richardson DR, Ponka P, (1997) The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331: 1-40.
17. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML, (2006) The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121: 144-158.
18. Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, et al. (2005) A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci U S A 102: 12095-12100.
19. Shterman N, Kupfer B, Moroz C, (1991) Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology 59: 19-25.
20. Ba Q, Hao M, Huang H, Hou J, Ge S, et al. (2011) Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin Cancer Res 17: 7625-7633.
21. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468.
22. Le NT, Richardson DR, (2004) Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104: 2967-2975.
23. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, et al. (2000) A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5: 299-309.
24. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, et al. (2000) Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403: 776-781.
25. Wang LH, Rothberg KG, Anderson RG, (1993) Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 123: 1107-1117.
26. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, et al. (1992) Caveolin, a protein component of caveolae membrane coats. Cell 68: 673-682.
27. Doherty GJ, McMahon HT, (2009) Mechanisms of endocytosis. Annu Rev Biochem 78: 857-902.
28. Wartenberg M, Wolf S, Budde P, Grunheck F, Acker H, et al. (2003) The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab Invest 83: 1647-1655.
29. He Y, Fan J, Lin H, Yang X, Ye Y, et al. (2011) The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alpha in human rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int 31: 53-60.
30. Huang XJ, Ma ZQ, Zhang WP, Lu YB, Wei EQ, (2007) Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J Pharm Pharmacol 59: 849-856.
31. Riganti C, Doublier S, Viarisio D, Miraglia E, Pescarmona G, et al. (2009) Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br J Pharmacol 156: 1054-1066.
32. Horonchik L, Wessling-Resnick M, (2008) The small-molecule iron transport inhibitor ferristatin/NSC306711 promotes degradation of the transferrin receptor. Chem Biol 15: 647-653.
33. Daniels TR, Delgado T, Helguera G, Penichet ML, (2006) The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121: 159-176.